Table of Contents
In a 24-person Johns Hopkins study, antidepressant effects from psilocybin combined with supportive psychotherapy lasted at least a year in some patients with moderate to severe major depressive disorder. A separate small 2025 trial found similar durability in veterans, though most effects began to fade after nine months. Both are early, small studies.
- Duration sets psilocybin apart: Researchers note that a single psilocybin session may produce antidepressant effects lasting months, compared to daily medications that can take weeks to begin working.
- Treatment-resistant patients are the focus: Experts cited in the source consistently emphasize that the most promising candidates are people who have not responded to existing therapies, not the general population.
- MDMA hit a regulatory wall: In 2024, the FDA declined to approve MDMA-assisted therapy for PTSD after its advisory panel raised doubts about both safety and efficacy data.
- Ibogaine carries documented safety risks: The executive order named ibogaine specifically, but most human evidence remains limited, and published research has linked it to potentially fatal cardiac arrhythmias.
- Model
- human
- Sample
- 24 adults with moderate to severe major depressive disorder (Johns Hopkins, 2022); separate small 2025 cohort of U.S. veterans with treatment-resistant depression
- Dose
- Psilocybin-assisted treatment (specific doses not reported in source)
- Design
- Observational follow-up over up to 12 months
- Key outcome
- Antidepressant effects persisted for at least a year in some patients in the 2022 study; most effects in the 2025 veteran study began to wane after nine months
- Main limitation
- Very small sample sizes; results cannot be generalized to the broader population
What the Research Examined
The ABC News article is a news report, not a primary study. It draws on two published clinical investigations and expert commentary gathered in the context of President Trump’s April 2026 executive order directing the FDA to expedite its review of psychedelic-based therapies. The underlying research it references includes a 2022 Johns Hopkins study published in the Journal of Psychopharmacology that followed 24 adults with moderate to severe major depressive disorder through up to one year of psilocybin-assisted treatment, and a small 2025 study assessing a single psilocybin dose in U.S. veterans with treatment-resistant depression.
Frederick Barrett, director of the Center for Psychedelic and Consciousness Research at Johns Hopkins School of Medicine, and Alex Kwan, a professor of biomedical engineering at Cornell University, both spoke to ABC News about the state of the science. Barrett framed the executive order as a potential facilitator of the safety and efficacy work still needed, rather than a shortcut around it. Kwan highlighted two properties that distinguish psilocybin from conventional antidepressants: a faster onset and a mechanism of action that may reach patients who do not respond to SSRIs. If you want to situate these findings within the broader landscape of psilocybin research and mental health, the evidence base is growing but still early.
The source also covers MDMA, which failed to receive FDA approval for PTSD treatment in 2024 after an advisory panel voted against it on both efficacy and safety grounds, and ibogaine, named directly in the executive order, which carries documented risks including potentially fatal cardiac arrhythmias. The executive order further directs the Attorney General and the Department of Health and Human Services to review rescheduling for Schedule I substances that have completed late-stage clinical trials, a step researchers say could ease access for scientific study.
What the Findings Show
- 12-month durability (2022 Hopkins study).In a 24-person trial, antidepressant effects from psilocybin combined with supportive psychotherapy were reported to last at least one year in some patients with moderate to severe major depressive disorder.
- Veteran cohort follow-up (2025).A small 2025 study of U.S. veterans with treatment-resistant depression found some participants experienced reductions in depressive symptoms for up to 12 months after a single psilocybin dose, though most effects began to wane after nine months.
- MDMA advisory outcome (2024).A majority of the FDA’s Psychopharmacologic Drugs Advisory Committee voted against recommending approval of pharmaceutical MDMA combined with therapy for PTSD, citing doubts about efficacy data and the risk-benefit balance. The FDA followed that guidance two months later.
- Ibogaine safety signal.Published evidence cited in the source suggests ibogaine carries serious safety risks, including potentially fatal cardiac arrhythmias, as well as neurologic and gastrointestinal side effects. Most human evidence for ibogaine remains limited to small, early studies.
Taken together, these data points sketch a field that is advancing but uneven. Psilocybin has the most encouraging human durability data so far, MDMA has faced its first major regulatory setback, and ibogaine sits at the earliest stage of credible human evidence while carrying a documented cardiac risk profile. Barrett’s public comments, as reported by ABC News, capture the professional consensus well: the results are encouraging in carefully screened, professionally supervised settings, but these substances are not appropriate for unsupervised use, and no therapy works for everyone.
How long do the antidepressant effects of psilocybin last based on current research?
In a small Johns Hopkins clinical study, some patients with major depressive disorder maintained antidepressant effects for at least a year after psilocybin-assisted treatment. A separate small 2025 study in veterans found effects in most participants began to fade after about nine months. Both studies are limited by small sample sizes.
What This Is, and What It Is Not
This is This recap is based on a news article that summarizes two small clinical studies and expert commentary; it is not a systematic review or a direct analysis of primary data.
This is not This is not medical advice, a treatment recommendation, or evidence that psilocybin is approved or safe for self-directed use. Small pilot studies cannot establish efficacy or safety for a general population, and no psychedelic therapy discussed here is currently approved by the FDA for the conditions mentioned.
Our Take
Within our community, we hold psilocybin as a sacrament, and part of that reverence is taking the science seriously on its own terms. What these early studies suggest is not a miracle but a signal, one worth following with rigor and honesty. The experts quoted here are not psychedelic enthusiasts making promises; they are clinical researchers urging caution and proper process even as they note genuine promise. That combination of openness and care is something our tradition has always understood. The executive order may or may not accelerate what matters most, which is patient safety. We will keep watching the primary literature and reporting what it actually says.
If you are drawn to understanding the science behind psilocybin’s potential, we welcome you to explore what researchers are learning, slowly and carefully, about how these medicines interact with the mind. Whatever station of the journey you find yourself in, Grounding or Integration or somewhere between, we believe informed curiosity is its own form of preparation. Read widely, question generously, and never make a medical decision based on a news cycle or a policy announcement. We are glad you are here.
Frequently Asked Questions
Has the FDA approved psilocybin for depression or PTSD?
No. As of the source publication date, psilocybin is not FDA-approved for any mental health condition. It remains a Schedule I controlled substance. The executive order directs the FDA to expedite its review process, but no approval has been granted.
What did Trump’s executive order on psychedelics actually do?
The April 2026 executive order directed the FDA to speed up review of certain psychedelics, asked the Attorney General and HHS to consider rescheduling substances that have passed late-stage clinical trials, and specifically named ibogaine as a compound of interest for conditions including PTSD and depression.
Why did the FDA reject MDMA therapy for PTSD?
In 2024, the FDA’s advisory panel voted against recommending approval because of doubts about the efficacy data and whether the benefits of MDMA-assisted therapy outweigh its risks for PTSD patients. The FDA formally declined approval two months after the panel vote.
Is ibogaine safe to use for depression or PTSD?
The evidence base for ibogaine is limited, consisting mostly of animal studies and small early human studies. Published research has linked it to serious safety risks including potentially fatal cardiac arrhythmias. Experts recommend it should only be considered in a carefully supervised clinical context.
Who benefits most from psychedelic-assisted therapy according to researchers?
According to experts cited in the source, patients who benefit most are those who have not responded to existing treatments, so-called treatment-resistant cases. Researchers stress that all current positive results come from carefully screened individuals monitored by trained professionals, not from unsupervised use.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
